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Cystic fibrosis (CF) is characterized by chronic airway infection and inflammation, which accounts for most morbidity and deaths.
Exhaled nitric oxide (NO), elevated in most inflammatory lung diseases, is decreased in CF, suggesting decreased formation, increased
metabolism or loss of NO. The nitrogen oxide metabolism in CF airways is complex and not yet fully understood.
In this article we will summarize current understanding of the origin and function of NO in (patho)physiological processes in the lung of
normal subjects and CF patients, possible explanations for and consequences of reduced NO concentrations in CF and possible therapetic
strategies for treatment of CF patients.
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Cystic fibrosis is characterized by chronic bacterial lung
infections, mostly with Pseudomonas aeruginosa, intense
neutrophil-dominated airway inflammation and progressive
decline of lung function, which is the major cause of
morbidity and mortality [1].
Nitric oxide (NO) has shown to be important in a variety
of regulatory processes in the lung, including host defence,
inflammation and bronchomotor control [2]. NO concen-
trations measured in exhaled air are highly variable but are
generally increased in inflammatory lung diseases like
asthma and bronchiectasis [3–5]. It is surprising that,
despite chronic inflammation of the lungs in CF patients,
the amount of exhaled NO is not increased, or even
decreased. Nasal NO is significantly lower in CF patients
than in controls [3,6,7] and bronchial NO levels are not
different [3,6,8] or decreased compared to levels in control
subjects [7,9,10].1569-1993/$ - see front matter D 2005 European Cystic Fibrosis Society. Publish
doi:10.1016/j.jcf.2005.05.008
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E-mail address: k.dewinter@umcutrecht.nl (K.M. de Winter-de Groot).In this article we will review the origin and function of
NO in (patho)physiological processes in the lung of normal
subjects and CF patients. Subsequently we focus on possible
explanations for and consequences of reduced NO levels in
CF patients and on the role of NO in therapeutic strategies
for treatment of CF patients.2. Origin, function and interpretation of exhaled NO in
patients with CF
Nitric oxide (NO) is a free radical gas and messenger
molecule which is produced in the respiratory tract and is
detectable in exhaled air. The physiological role of exhaled
NO probably includes modulation of ciliary activity,
mediation of inflammation, antimicrobial activity, vaso-
dilatation and bronchodilatation [2]. NO is formed by a
group of enzymes called NO synthases (NOS). These
enzyms catalyze l-arginine to form l-citrulline and NO.
There are three isoforms of NOS: neuronal NOS (NOS1),
inducible NOS (NOS2) and endothelial NOS (NOS3).
NOS1 and NOS3 are constitutively expressed and produce
small amounts of NO, whereas NOS2 is expressed
maximally following an inflammatory stimulus and produ-
ces relatively large quantities of NO, up to a 100-fold of the
constitutive production (Fig. 1).s 4 (2005) 25 – 29ed by Elsevier B.V. All rights reserved.
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Fig. 1. Possible causes and effects of low exhaled NO in CF lungs.
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known about the relative contribution of these various NOS
isoforms to the amount of NO in exhaled air.
NOS1 derived NO is thought to be the main neuro-
transmitter of nonadrenergic, noncholinergic (NANC)
nerves, and is involved in human bronchomotor control.
Abnormalities in NOS1 isoform may contribute to the
development of airway obstruction [12]. NOS3 is con-
stitutively expressed in pulmonary blood vessels, airway
epithelial cells and neutrophils. There is increasing
evidence that NOS3 contributes to NO related (patho)-
physiology in the airways [13]. It is NO produced by
NOS2 which has antimicrobial activity against bacteria,
viruses and fungi [14–16]. NOS2 in the lung can be
expressed by macrophages, neutrophils and bronchial
epithelial cells. The expression is upregulated by lip-
opolysaccharide (LPS) and by proinflammatory cytokines,
such as interleukin-1 (IL-1h), tumor necrosis factor (TNF)-
a and interferon (IFN)-g [17,18]. Induction of NO
synthases during airway inflammation results in increased
concentrations of exhaled NO, as is seen in asthma,
bronchiectasis or upper respiratory tract infection [3–5,19].
However, in patients with bronchiectasis also unchanged
values of airway NO are found [8].
Under pathophysiological circumstances an excessive
amount of NO causes inflammation, oxidative tissue
damage, plasma leakage and mucus secretion through active
intermediates [20].
In patients with CF exhaled NO is low. Different
correlations are found between exhaled NO and pulmonary
function in patients with CF. In some studies decreased NO
formation in lower airways correlated with more progressive
lung disease [8,9,21,22] whereas other studies found no
relationship [7,23,24]. Probably, measurement of lung
function and of exhaled NO give different information
about the inflammatory process of the airways. Airwayinflammation is only one of the many determinants of
airway obstruction.
Furthermore exhaled NO levels and sputum metabolites
concentrations in CF patients did not correlate with the
activity of airway inflammation since no significant
difference is observed between stable CF patients and
patients with exacerbations [8,21,25]. Some studies found
no changes in exhaled NO during treatment of an exacer-
bation with antibiotics [8,23] whereas others did [24]. This
suggests that exhaled NO is not a suitable marker to monitor
airway inflammation and to evaluate anti-inflammatory
treatment in CF patients with an infective pulmonary
exacerbation [23].
In patients with homozygosity for yF508 mutation, both
nasal and bronchial NO tend to be lower compared to non-
homozygous patients [7].3. Possible explanations for reduced exhaled NO
concentrations in patients with CF
As mentioned, considering the intense pulmonary inflam-
mation in CF, it is surprising that exhaled NO levels are not
increased. There are several possible explanations for these
observation. First of all the thick mucus lining the airways
could result in poor diffusion of NO into the gaseous phase.
The rate of degradation of NO in the aqueous phase is very
rapid and an increase in the volume of airway secretions
could reduce the concentration of NO in exhaled air. High
concentrations of the stable NO metabolites nitrate and
nitrite are detectable in CF airway secretions while exhaled
NO is not elevated. This suggests that a significant amount of
NO metabolites are retained in airway lining fluids [21] and
thus exhaled NO may not reflect the total NO production in
the airways [26]. The nasal sinuses are usually involved in
CF, and obstructed sinus ostia may be the cause for low nasal
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human paranasal sinuses, obstruction will block diffusion
into the nose [6,27].
Alternatively, a lack of the substrate (l-arginine) and
therefore decreased NO formation may contribute to the low
airway NO in CF. Supplementation of l-arginine, orally or
by infusion, can augment airway NO formation. However,
NO concentrations remain subnormal and an improvement
of pulmonary function is not observed [28,29].
Another explanation for low levels of exhaled NO may
be that the activity of NOS is reduced in airways of CF
patients. Immunohistochemistry showed that bronchial
epithelium from CF lungs stained less for NOS2 when
compared to controls, while inflammatory cells in CF
submucosa were strongly positive for NOS2. These results
were supported by in situ hybridization showing less NOS2
mRNA in CF epithelium than in controls. Stimulation with
cytokines (IL-1h, TNF-a, IFN-g) increased the expression
of NOS2 mRNA in cultures of normal, but not CF epithelial
cells [30]. Total NOS-specific activity was greatly reduced
in the trachea of CF mice. After treatment with LPS or the
NO substrate l-arginine, NO production failed to increase in
lungs of yF508 homozygous mice when compared with
wild type mice (cftr /). A similar effect was seen in wild
type mice treated with LPS and S-methylisothiourea (SMT),
a NOS2-specific inhibitor [31].
If failure of NOS2 upregulation is a cause for the low
levels of exhaled NO in CF patients, it remains unclear
whether this is an inherent lack of gene expression related to
the CFTR mutation, or whether it is secondary to chronic
infection and inflammation. The former hypothesis is
supported by immunostains which show absent constitutive
NOS2 expression in CF human and murine airway epithelial
cells [31]. Inhibition of CFTR function results in reduced
NOS2 mRNA in human tracheal epithelial cell lines, while
overexpression of human CFTR in mice intestinal epithe-
lium leads to NOS2 expression in the ileum [32]. CF infants
at birth have exhaled NO 3-fold lower than healthy controls,
also suggesting that the defect in NOS2 expression occurs
prior to the onset of recurrent infections and inflammation
[10].
The latter explanation seems likely in view of decreased
or unchanged NO levels in CF, bronchiectasis and primary
ciliary dyskinesia (PCD) [8,33–35]. These diseases are all
characterized by infection and inflammation, but there is no
CFTR dysfunction in bronchiectasis and PCD. Demonstra-
tion of normal NOS2 expression in inflammatory cells from
CF bronchial explants also suggests a normal gene [30].
Furthermore, it is shown that inflammation is already
present in very young infants with CF, even before clinical
symptoms of respiratory infection [36]. Hence, low exhaled
NO levels in this early stage of CF could already be
explained by inflammation.
Polymorphisms of constitutive NOS (NOS 1 and 3) can
contribute to variable NO formation. CF patients with high
AAT repeat numbers (12) at the relevant locus (12q24) ofthe NOS1 gene have lower bronchial and nasal NO and
airways of these patients are more frequently colonized with
P. aeruginosa and A. fumigatus [37,38]. For NOS3, the
894G variant in exon 7 of the NOS3 gene is associated with
lower bronchial NO and also an increased risk for
colonization with P. aeruginosa in female patients with
CF [13].
Another potential cause for low exhaled NO is that both
sputum ex vivo and P. aeruginosa in vitro consume NO,
probably due to the presence of NO reductase in P.
aeruginosa. Treatment of sputum with tobramycin inhibited
NO consumption due to an anti-pseudomonal effect [39].
Finally, it is plausible that an increased NO consumption/
metabolism by inflammatory oxidative processes (super-
oxide and/or myeloperoxidase (MPO) reaction) contributes
to a decreased exhaled NO in CF patients. CF patients have
increased serum NO2
/NO3
 levels and increased immunos-
taining of nitrotyrosine in airway epithelium, all NO
metabolites. Less NO will diffuse into the gaseous phase
and is, by that, not detectable in exhaled air [11,26].
Levels of exhaled NO concentrations in CF patients are
variable.
Differences in results may also partially be explained by
the use of different techniques for measurements of NO in
different studies.
Exhaled NO is usually determined during single-breath
exhalations. The recommended technique involves inspira-
tion of NO-free air to total lung capacity, followed
immediately by full exhalation at a rate of 50 mL/s through
a mouthpiece into a chemiluminescence analyser [40,41].
This manoeuvre is not applicable to very young or severely
affected children, although the ERS/ATS statement has
provided some practical suggestions. For detection of nasal
NO no standardized method is available yet.4. Possible pathophysiologic consequences of reduced
NO concentrations in patients with CF
As NO is a potent bronchodilator, an initial consequence
of low NO formation in advanced cystic fibrosis lung
disease may be bronchial obstruction.
Secondly, NO production reduced P. aeruginosa adher-
ence to human bronchial epithelial cells and enhanced
killing of internalized bacteria. A lack of epithelial NOS2 in
patients with CF may contribute to P. aeruginosa infection
and colonization [42]. The ability of the epithelium to clear
strains of P. aeruginosa is diminished in airways of yF508
homozygous mice [31]. A reduction of NOS2 expression
throughout the airway epithelium would severely hinder the
important first-line defense to bacterial infections. Besides
P. aeruginosa infections, this observed susceptibility does
count for Staphylococcus aureus, Burkholderia cepacia,
and fungi [16,37,43,44].
CF airway epithelial cells are also more susceptible to
respiratory virus infections because of impaired innate
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replication. Low NO levels, because of an impaired NOS2
signaling pathway in CF, reduce prevention of viral
replication [16,45].
Furthermore, NO activates soluble guanylate cyclase
(GC-S) and thus stimulates the production of cGMP. CGMP
effectively downregulates amiloride-sensitive sodium
absorption. A loss of NO production would result in
hyperabsorption of sodium across airway epithelium, a
common CF-associated characteristic. In mice, inhibition of
NOS2 showed an increased nasal transepithelial potential
difference, supporting the role of NO on membrane ion
transport [31].
As NO opposes neutrophil sequestration [46], reduced NO
levels in cystic fibrosis may promote the intense neutrophilic
infiltration that characterizes the disease. Human CF bron-
chial epithelial cells, unlike normal controls, were unable to
express NOS2 protein and mRNA in response to either
neutrophil co-culture or cytokine stimulation [47].
Finally, an increased metabolism of NO may result in
lower NO levels, but also in NO-mediated oxidative injury
which contributes to the pathobiology of CF lung disease
[11].5. Possible therapeutic strategies
Considering the important role of NO in the pathophysi-
ology of CF, future studies should focus on therapeutic
augmentation of NO and on possible positive effects on
pulmonary function in cystic fibrosis patients. Results of
some studies are already available.
Nasal breathing, i.e. autoinhalation of upper airway NO,
reduces pulmonary vascular resistance, improves arterial
oxygenation and maintains the bronchomuscular tone in
subjects without lung disease [48]. However, inhalation of
NO, at either physiological or therapeutical levels had no
effect on pulmonary function in patients with CF [49]. The
same authors studied the effect of administration of l-
arginine infusion and oral l-arginine to CF patients. After
infusion of l-arginine, nasally and bronchially derived NO
concentrations increased significantly in CF patients, but
remained subnormal when compared with baseline values of
controls. Moreover, pulmonary function remained
unchanged [29]. Supplementation of oral l-arginine can
augment airway NO formation in CF patients, however, NO
concentrations remained subnormal and an improvement in
pulmonary function was not observed [28].
As retention and metabolisation of NO within viscous
airway secretions may cause low concentrations of exhaled
NO, alterations of exhaled NO and lung function after
treatment with recombinant human DNase I (dornase alpha)
were studied in a group of children with CF [50]. Dornase
alpha modifies CF airway secretions by cleaving DNA in
shorter fractions, helping individuals with CF to clear their
airways of purulent secretions [51]. A significant positivecorrelation of airway NO concentrations was observed with
lung function in young CF patients treated with dornase
alpha as compared to patients treated with placebo. This
correlation seems to support the hypothesis of retention of
NO metabolites in thick airway mucus as a cause of low
exhaled NO in CF patients.
As increased levels of inflammatory oxidants or oxida-
tion products in airway secretions may play a role in the
occurrence of oxidative stress and damage in the respiratory
tract of CF airways, modifications of these pathways may be
useful targets for therapeutic strategies [11].
Further studies are needed to elucidate the precise
mechanisms of NO-related (patho)physiology in the air-
ways of healthy subjects and patients with cystic fibrosis,
which will hopefully lead to more effective therapeutic
interventions.References
[1] Ratjen F, Doring G. Cystic fibrosis. Lancet 2003;361:681–9.
[2] Barnes PJ, Belvisi MG. Nitric oxide and lung disease. Thorax 1993;
48:1034–43.
[3] Lundberg JO, Nordvall SL, Weitzberg E, Kollberg H, Alving K.
Exhaled nitric oxide in paediatric asthma and cystic fibrosis. Arch Dis
Child 1996;75:323–6.
[4] Alving K, Weitzberg E, Lundberg JM. Increased amount of nitric
oxide in exhaled air of asthmatics. Eur Respir J 1993;6:1368–70.
[5] Kharitonov SA, Wells AU, O’Connor BJ, Cole PJ, Hansell DM,
Logan-Sinclair RB, et al. Elevated levels of exhaled nitric oxide in
bronchiectasis. Am J Respir Crit Care Med 1995;151:1889–93.
[6] Balfour-Lynn IM, Laverty A, Dinwiddie R. Reduced upper airway
nitric oxide in cystic fibrosis. Arch Dis Child 1996;75:319–22.
[7] Thomas SR, Kharitonov SA, Scott SF, Hodson ME, Barnes PJ. Nasal
and exhaled nitric oxide is reduced in adult patients with cystic fibrosis
and does not correlate with cystic fibrosis genotype. Chest 2000;117:
1085–9.
[8] Ho LP, Innes JA, Greening AP. Exhaled nitric oxide is not elevated in
the inflammatory airways diseases of cystic fibrosis and bronchiecta-
sis. Eur Respir J 1998;12:1290–4.
[9] Grasemann H, Michler E, Wallot M, Ratjen F. Decreased concen-
tration of exhaled nitric oxide (NO) in patients with cystic fibrosis.
Pediatr Pulmonol 1997;24:173–7.
[10] Elphick HE, Demoncheaux EA, Ritson S, Higenbottam TW, Everard
ML. Exhaled nitric oxide is reduced in infants with cystic fibrosis.
Thorax 2001;56:151–2.
[11] Morrissey BM, Schilling K, Weil JV, Silkoff PE, Rodman DM. Nitric
oxide and protein nitration in the cystic fibrosis airway. Arch Biochem
Biophys 2002;406:33–9.
[12] Belvisi MG, Ward JK, Mitchell JA, Barnes PJ. Nitric oxide as a
neurotransmitter in human airways. Arch Int Pharmacodyn Ther 1995;
329:97–110.
[13] Grasemann H, van’s Gravesande KS, Buscher R, Knauer N, Silverman
ES, Palmer LJ, et al. Endothelial nitric oxide synthase variants in
cystic fibrosis lung disease. Am J Respir Crit Care Med 2003;167:
390–4.
[14] Fang FC. Perspectives series: host/pathogen interactions. Mechanisms
of nitric oxide-related antimicrobial activity. J Clin Invest 1997;99:
2818–25.
[15] Sanders SP, Siekierski ES, Porter JD, Richards SM, Proud D. Nitric
oxide inhibits rhinovirus-induced cytokine production and viral
replication in a human respiratory epithelial cell line. J Virol 1998;
72:934–42.
K.M. de Winter-de Groot, C.K. van der Ent / Journal of Cystic Fibrosis 4 (2005) 25–29 29[16] Zheng S, De BP, Choudhary S, Comhair SA, Goggans T, Slee R, et al.
Impaired innate host defense causes susceptibility to respiratory virus
infections in cystic fibrosis. Immunity 2003;18:619–30.
[17] Robbins RA, Barnes PJ, Springall DR, Warren JB, Kwon OJ, Buttery
LD, et al. Expression of inducible nitric oxide in human lung epithelial
cells. Biochem Biophys Res Commun 1994;203:209–18.
[18] Salkowski CA, Detore G, McNally R, van Rooijen N, Vogel SN.
Regulation of inducible nitric oxide synthase messenger RNA
expression and nitric oxide production by lipopolysaccharide in vivo:
the roles of macrophages, endogenous IFN-gamma, and TNF receptor-
1-mediated signaling. J Immunol 1997;158:905–12.
[19] Kharitonov SA, Yates D, Barnes PJ. Increased nitric oxide in exhaled
air of normal human subjects with upper respiratory tract infections.
Eur Respir J 1995;8:295–7.
[20] Barnes PJ, Liew FY. Nitric oxide and asthmatic inflammation.
Immunol Today 1995;16:128–30.
[21] Grasemann H, Ioannidis I, Tomkiewicz RP, de Groot H, Rubin BK,
Ratjen F. Nitric oxide metabolites in cystic fibrosis lung disease. Arch
Dis Child 1998;78:49–53.
[22] Texereau J, Marullo S, Hubert D, Coste J, Dusser DJ, Dall’Ava-
Santucci J, et al. Nitric oxide synthase 1 as a potential modifier gene of
decline in lung function in patients with cystic fibrosis. Thorax
2004;59:156–8.
[23] Jobsis Q, Raatgeep HC, Schellekens SL, Kroesbergen A, Hop WC, de
Jongste JC. Hydrogen peroxide and nitric oxide in exhaled air of
children with cystic fibrosis during antibiotic treatment. Eur Respir J
2000;16:95–100.
[24] Jaffe A, Slade G, Rae J, Laverty A. Exhaled nitric oxide increases
following admission for intravenous antibiotics in children with cystic
fibrosis. J Cyst Fibros 2003;2:143–7.
[25] Ojoo JC, Mulrennan SA, Kastelik JA, Morice AH, Redington AE.
Exhaled breath condensate pH and exhaled nitric oxide in allergic
asthma and in cystic fibrosis. Thorax 2005;60:22–6.
[26] Jones KL, Hegab AH, Hillman BC, Simpson KL, Jinkins PA, Grisham
MB, et al. Elevation of nitrotyrosine and nitrate concentrations in
cystic fibrosis sputum. Pediatr Pulmonol 2000;30:79–85.
[27] Lundberg JO, Farkas-Szallasi T, Weitzberg E, Rinder J, Lindholm J,
Anggaard A, et al. High nitric oxide production in human paranasal
sinuses. Nat Med 1995;1:370–3.
[28] Grasemann H, Grasemann C, Kurtz F, Tietze-Schillings G, Vester U,
Ratjen F. Oral l-arginine supplementation in cystic fibrosis patients: a
placebo-controlled study. Eur Respir J 2005;25:62–8.
[29] Grasemann H, Gartig SS, Wiesemann HG, Teschler H, Konietzko N,
Ratjen F. Effect of l-arginine infusion on airway NO in cystic fibrosis
and primary ciliary dyskinesia syndrome. Eur Respir J 1999;13:114–8.
[30] Meng QH, Springall DR, Bishop AE, Morgan K, Evans TJ, Habib S, et
al. Lack of inducible nitric oxide synthase in bronchial epithelium: a
possible mechanism of susceptibility to infection in cystic fibrosis. J
Pathol 1998;184:323–31.
[31] Kelley TJ, Drumm ML. Inducible nitric oxide synthase expression is
reduced in cystic fibrosis murine and human airway epithelial cells.
J Clin Invest 1998;102:1200–7.
[32] Steagall WK, Elmer HL, Brady KG, Kelley TJ. Cystic fibrosis
transmembrane conductance regulator-dependent regulation of epithe-
lial inducible nitric oxide synthase expression. Am J Respir Cell Mol
Biol 2000;22:45–50.
[33] Lundberg JO, Weitzberg E, Nordvall SL, Kuylenstierna R, Lundberg
JM, Alving K. Primarily nasal origin of exhaled nitric oxide and
absence in Kartagener’s syndrome. Eur Respir J 1994;7:1501–4.
[34] Karadag B, James AJ, Gultekin E, Wilson NM, Bush A. Nasal and
lower airway level of nitric oxide in children with primary ciliary
dyskinesia. Eur Respir J 1999;13:1402–5.[35] Tsang KW, Leung R, Fung PC, Chan SL, Tipoe GL, Ooi GC, et al.
Exhaled and sputum nitric oxide in bronchiectasis: correlation with
clinical parameters. Chest 2002;121:88–94.
[36] Khan TZ, Wagener JS, Bost T, Martinez J, Accurso FJ, Riches DW.
Early pulmonary inflammation in infants with cystic fibrosis. Am J
Respir Crit Care Med 1995;151:1075–82.
[37] Grasemann H, Knauer N, Buscher R, Hubner K, Drazen JM, Ratjen F.
Airway nitric oxide levels in cystic fibrosis patients are related to a
polymorphism in the neuronal nitric oxide synthase gene. Am J Respir
Crit Care Med 2000;162:2172–6.
[38] Grasemann H, van’s Storm GK, Gartig S, Kirsch M, Buscher R,
Drazen JM, et al. Nasal nitric oxide levels in cystic fibrosis
patients are associated with a neuronal NO synthase (NOS1) gene
polymorphism. Nitric Oxide 2002;6:236–41.
[39] Gaston B, Ratjen F, Vaughan JW, Malhotra NR, Canady RG, Synder
AH, et al. Nitrogen redox balance in the cystic fibrosis airway:
effects of antipseudomonal therapy. Am J Respir Crit Care Med
2002;165:387–90.
[40] Recommendations for standardized procedures for the on-line and
off-line measurement of exhaled lower respiratory nitric oxide and
nasal nitric oxide in adults and children-1999. This official
statement of the American Thoracic Society was adopted by the
ATS Board of Directors, July 1999. Am J Respir Crit Care Med
1999;160:2104–17.
[41] Baraldi E, de Jongste JC. Measurement of exhaled nitric oxide in
children, 2001. Eur Respir J 2002;20:223–37.
[42] Darling KE, Evans TJ. Effects of nitric oxide on Pseudomonas
aeruginosa infection of epithelial cells from a human respiratory cell
line derived from a patient with cystic fibrosis. Infect Immun 2003;71:
2341–9.
[43] Malawista SE, Montgomery RR, van Blaricom G. Evidence for
reactive nitrogen intermediates in killing of staphylococci by human
neutrophil cytoplasts. A new microbicidal pathway for polymorpho-
nuclear leukocytes. J Clin Invest 1992;90:631–6.
[44] Smith AW, Green J, Eden CE, Watson ML. Nitric oxide-induced
potentiation of the killing of Burkholderia cepacia by reactive oxygen
species: implications for cystic fibrosis. J Med Microbiol 1999;48:
419–23.
[45] Zheng S, Xu W, Bose S, Banerjee AK, Haque SJ, Erzurum SC.
Impaired nitric oxide synthase-2 signaling pathway in cystic fibrosis
airway epithelium. Am J Physiol Lung Cell Mol Physiol 2004;287:
L374–81.
[46] Sato Y, Walley KR, Klut ME, English D, D’yachkova Y, Hogg JC, et
al. Nitric oxide reduces the sequestration of polymorphonuclear
leukocytes in lung by changing deformability and CD18 expression.
Am J Respir Crit Care Med 1999;159:1469–76.
[47] Meng QH, Polak JM, Edgar AJ, Chacon MR, Evans TJ, Gruenert DC,
et al. Neutrophils enhance expression of inducible nitric oxide
synthase in human normal but not cystic fibrosis bronchial epithelial
cells. J Pathol 2000;190:126–32.
[48] Lundberg JO, Settergren G, Gelinder S, Lundberg JM, Alving K,
Weitzberg E. Inhalation of nasally derived nitric oxide modulates
pulmonary function in humans. Acta Physiol Scand 1996;158:
343–7.
[49] Ratjen F, Gartig S, Wiesemann HG, Grasemann H. Effect of inhaled
nitric oxide on pulmonary function in cystic fibrosis. Respir Med
1999;93:579–83.
[50] Grasemann H, Lax H, Treseler JW, Colin AA. Dornase alpha and
exhaled NO in cystic fibrosis. Pediatr Pulmonol 2004;38:379–85.
[51] Shak S, Capon DJ, Hellmiss R, Marsters SA, Baker CL. Recombinant
human DNase I reduces the viscosity of cystic fibrosis sputum. Proc
Natl Acad Sci U S A 1990;87:9188–92.
